Intravenous immunoglobulin + subcutaneous immunoglobulin (SCIG) ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 11 | Myasthenia gravis | 1 |
11. Myasthenia gravis
Clinical trials : 332 / Drugs : 234 - (DrugBank : 81) / Drug target genes : 45 - Drug target pathways : 127
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04728425 (ClinicalTrials.gov) | August 28, 2020 | 14/7/2020 | Subcutaneous Immunoglobulin for Myasthenia Gravis | Efficacy and Safety of Subcutaneous Immunoglobulin in Patients With Myasthenia Gravis | Myasthenia Gravis | Drug: subcutaneous immunoglobulin (SCIG);Drug: intravenous immunoglobulin + subcutaneous immunoglobulin (SCIG) | University Health Network, Toronto | NULL | Recruiting | 18 Years | 100 Years | All | 30 | Phase 2 | Canada |